Background
Background Bipolar disorder has Bipolar disorder has been ranked seventh among the worldbeen ranked seventh among the worldwide causes of non-fatal disease burden. wide causes of non-fatal disease burden.
Aims Aims To estimate the cost-effectiveness
To estimate the cost-effectiveness of interventions for reducing the global of interventions for reducing the global burden of bipolar disorder. burden of bipolar disorder.
Method
Method Hospital-and communityHospital-and communitybased delivery of two generic mood based delivery of two generic mood stabilisers (lithium and valproic acid), stabilisers (lithium and valproic acid), alone and in combination with alone and in combination with psychosocial treatment, were modelled psychosocial treatment, were modelled for14 global sub-regions. A population for14 global sub-regions. A population model was employed to estimate the model was employed to estimate the impact of different strategies, relative to impact of different strategies, relative to no intervention.Total costs (in interno intervention.Total costs (in international dollars (I$)) and effectiveness national dollars (I$)) and effectiveness (disability-adjusted life years (DALYs) (disability-adjusted life years (DALYs) averted) were combined to form costaverted) were combined to form costeffectiveness ratios. effectiveness ratios.
Results

Results Baseline results showedlithium
Baseline results showedlithium to be no more costly yet more effective to be no more costly yet more effective than valproic acid, assuming an antithan valproic acid, assuming an antisuicidal effect for lithium but not for suicidal effect for lithium but not for valproic acid.Community-based valproic acid.Community-based treatment with lithium and psychosocial treatment with lithium and psychosocial care was most cost-effective (cost per care was most cost-effective (cost per DALY averted:I$2165^6475 in developing DALY averted:I$2165^6475 in developing sub-regions; I$5487^21123 in developed sub-regions; I$5487^21123 in developed sub-regions). sub-regions).
Conclusions
Conclusions Community-based interCommunity-based interventions for bipolar disorder were ventions for bipolar disorder were estimated to be more efficient than estimated to be more efficient than hospital-based services, each DALY hospital-based services, each DALY averted costing between one and three averted costing between one and three times average gross national income. times average gross national income.
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Bipolar affective disorder is an ICD-10 Bipolar affective disorder is an ICD-10 mental disorder characterised by at least mental disorder characterised by at least two episodes involving clinically significant two episodes involving clinically significant disturbed mood, energy and activity (World disturbed mood, energy and activity (World Health Organization, 1992). PopulationHealth Organization, 1992). Populationbased studies using similar methods in ten based studies using similar methods in ten countries have estimated prevalence rates countries have estimated prevalence rates ranging from 0.3% in Taiwan to 1.5% in ranging from 0.3% in Taiwan to 1.5% in New Zealand (Weissman New Zealand (Weissman et al et al, 1996) . , 1996). Bipolar disorder has been ranked seventh Bipolar disorder has been ranked seventh among the worldwide causes of non-fatal among the worldwide causes of non-fatal disease burden (World Health Organizadisease burden ( . Internationally, little is known about the relative ally, little is known about the relative cost-effectiveness of treatments for bipolar cost-effectiveness of treatments for bipolar affective disorder, particularly at the level affective disorder, particularly at the level of total (rather than clinical) populations. of total (rather than clinical) populations. This study examined the cost-effectiveness This study examined the cost-effectiveness of key clinical interventions (moodof key clinical interventions (moodstabilising drugs, with or without psychostabilising drugs, with or without psychosocial treatment) at the global level. social treatment) at the global level.
METHOD METHOD
Cost-effectiveness framework Cost-effectiveness framework
The World Health Organization (WHO) The World Health Organization (WHO) currently has a programme entitled currently has a programme entitled CHOosing Interventions that are CostCHOosing Interventions that are CostEffective (WHO-CHOICE). Using uniform Effective (WHO-CHOICE). Using uniform methodology, the project has generated methodology, the project has generated cost-effectiveness data in 14 sub-regions of cost-effectiveness data in 14 sub-regions of the world for key interventions capable of the world for key interventions capable of reducing leading contributors to disease reducing leading contributors to disease burden (http://www.who.int/evidence/cea). burden (http://www.who.int/evidence/cea). A standardised approach for cost-A standardised approach for costeffectiveness analysis has been developed effectiveness analysis has been developed (Tan Torres (Tan Torres et al et al, 2003) . A core feature of , 2003). A core feature of the approach is that costs and effects of the approach is that costs and effects of strategies are compared with a starting strategies are compared with a starting point of no intervention, which enhances point of no intervention, which enhances the generalisability of findings (since 'usual the generalisability of findings (since 'usual care' varies between settings). care' varies between settings).
Setting Setting
The 192 member states of the WHO were The 192 member states of the WHO were divided into five mortality strata based on divided into five mortality strata based on child and adult mortality rates (World child and adult mortality rates (World Health Organization, 2001 ). When these Health Organization, 2001). When these strata were applied to the six WHO strata were applied to the six WHO regions, they gave rise to 14 epidemioregions, they gave rise to 14 epidemiologically defined sub-regions (Table 1) . logically defined sub-regions (Table 1) . Intervention costs and effects were Intervention costs and effects were modelled at the total population level in modelled at the total population level in each sub-region and have been derived in each sub-region and have been derived in a way that allows for contextualised a way that allows for contextualised analyses at the country level. analyses at the country level. ). Key transition rates include the incidence of transition rates include the incidence of bipolar disorder in the population, case bipolar disorder in the population, case fatality and remission (defined as full fatality and remission (defined as full recovery of a case). In addition, a disability recovery of a case). In addition, a disability weight is specified (on a 0-1 scale, where weight is specified (on a 0-1 scale, where 0 equals no disability) for time spent in 0 equals no disability) for time spent in different mood states. different mood states.
Population model
People with bipolar disorder are People with bipolar disorder are modelled to live in one of three health modelled to live in one of three health states: (a) manic episodes, (b) depressive states: (a) manic episodes, (b) depressive episodes, or (c) relatively euthymic health episodes, or (c) relatively euthymic health states during which persons are nonstates during which persons are nonsymptomatic or symptomatic below the symptomatic or symptomatic below the threshold of a manic or depressive episode. threshold of a manic or depressive episode. In our model, treatment has two possible In our model, treatment has two possible effects: (a) a change in the distribution of effects: (a) a change in the distribution of time spent in each state (treated cases spend time spent in each state (treated cases spend more time in the intermittent health state more time in the intermittent health state and thus experience less disability) and (b) and thus experience less disability) and (b) a change in the case fatality rate (reduced a change in the case fatality rate (reduced suicide). Interventions have suicide). Interventions have no no effect on rates effect on rates of incidence (i.e. onset of bipolar disorder is of incidence (i.e. onset of bipolar disorder is not prevented) or remission (i.e. the average not prevented) or remission (i.e. the average duration of a case is not reduced). duration of a case is not reduced).
Using a lifetime analytical horizon, but Using a lifetime analytical horizon, but a 10-year treatment implementation period, a 10-year treatment implementation period, population-level effects were derived by population-level effects were derived by comparing number of healthy years lived comparing number of healthy years lived by the population with and without interby the population with and without intervention. The difference between these two vention. The difference between these two simulations represents the population-level simulations represents the population-level health gain (disability-adjusted life years health gain (disability-adjusted life years (DALYs) averted) resulting from interven-(DALYs) averted) resulting from intervention, relative to the situation of doing tion, relative to the situation of doing nothing. In the base case analysis, nonnothing. In the base case analysis, nonuniform age weights (which give less weight uniform age weights (which give less weight to years lived at young and older ages) and to years lived at young and older ages) and a 3% discount rate were used, with the a 3% discount rate were used, with the impact of these social preferences evaluated impact of these social preferences evaluated via sensitivity analysis. via sensitivity analysis.
Natural history of ICD^10 Natural history of ICD^10 bipolar disorder bipolar disorder
The Global Burden of Disease Study (GBD The Global Burden of Disease Study (GBD 2000) has generated age-and gender-specific 2000) has generated age-and gender-specific data on the prevalence, incidence and case data on the prevalence, incidence and case fatality of persons with bipolar disorder fatality of persons with bipolar disorder for different regions (http://www.who.int/ for different regions (http://www.who.int/ evidence/bod; Ayuso-Mateos, 2001). Prevaevidence/bod; Ayuso-Mateos, 2001). Prevalence rates for bipolar disorder from the lence rates for bipolar disorder from the GBD 2000 are shown in Table 1. Since  GBD 2000 are shown in Table 1 . Since the onset of bipolar disorder is not preventhe onset of bipolar disorder is not preventable by health intervention, current incitable by health intervention, current incidence coincides with natural (untreated) dence coincides with natural (untreated) history. Remission was calculated based history. Remission was calculated based on data from Angst & Preisig (1995) , on data from Angst & Preisig (1995) , who reported a 16% remission ratewho reported a 16% remission ratedefined as being episode-free for 5 defined as being episode-free for 5 years -after an average follow-up period years -after an average follow-up period of 21 years, equivalent to a yearly rate of of 21 years, equivalent to a yearly rate of less than 1%. Case fatality rates were calculess than 1%. Case fatality rates were calculated based on a standardised mortality lated based on a standardised mortality ratio of 2.5, a weighted average from four ratio of 2.5, a weighted average from four natural history studies for the pre-lithium natural history studies for the pre-lithium treatment era (e.g. Helgason, 1964; others treatment era (e.g. Helgason, 1964; others listed under Table 13a in Harris &  listed under Table 13a in Harris & Barraclough, 1998). Barraclough, 1998).
For the disability weight of untreated For the disability weight of untreated bipolar disorder, similar assumptions to bipolar disorder, similar assumptions to those employed by GBD 2000 were used, those employed by GBD 2000 were used, namely applying the same Dutch disability namely applying the same Dutch disability weight for a manic episode as for psychosis weight for a manic episode as for psychosis (0.72, where 0 equals no disability), and (0.72, where 0 equals no disability), and likewise for a (severe) depressive episode likewise for a (severe) depressive episode (0.76). A valuation of 0.14 for the intermit-(0.76). A valuation of 0.14 for the intermittent state of euthymia was taken to be tent state of euthymia was taken to be equivalent to mild depression (Ayusoequivalent to mild depression (Ayuso- v. manic manic episodes (a ratio of 3:1). The composite episodes (a ratio of 3:1). The composite disability weight of untreated bipolar disordisability weight of untreated bipolar disorder was therefore calculated to be 0.445 der was therefore calculated to be 0.445 (Table 2) . (Table 2 ).
Estimation of intervention Estimation of intervention effectiveness effectiveness
Analyses were limited to first-line intervenAnalyses were limited to first-line interventions. In strict terms, only the conventional tions. In strict terms, only the conventional mood-stabilising drug lithium meets the crimood-stabilising drug lithium meets the criteria for proven efficacy in the acute and teria for proven efficacy in the acute and prophylactic treatment of both manic and prophylactic treatment of both manic and depressive episodes (Bauer & Mitchner, depressive episodes (Bauer & Mitchner, 2004) , but these strict criteria were relaxed 2004), but these strict criteria were relaxed at least to include a comparator drug for at least to include a comparator drug for 5 6 0 5 6 0 AUTHOR'S PROOF AUTHOR'S PROOF Owing to the restricted level of evidence for these restricted level of evidence for these longer-term outcomes (intensive treatment longer-term outcomes (intensive treatment regimens tested within specialist study regimens tested within specialist study settings in high-income countries), effects settings in high-income countries), effects of psychosocial treatment were confined of psychosocial treatment were confined to improved adherence. to improved adherence. Table 2 documents the reduced dura- Table 2 documents the reduced duration of time spent in a manic or depressed tion of time spent in a manic or depressed state due to acute and prophylactic treatstate due to acute and prophylactic treatment (resulting in lower disability), first ment (resulting in lower disability), first under optimal conditions (efficacy), then under optimal conditions (efficacy), then adjusting for adherence and treatment adjusting for adherence and treatment coverage to derive an estimate of coverage to derive an estimate of population-level effectiveness. An acute population-level effectiveness. An acute treatment effect was calculated as the treatment effect was calculated as the product of response rate and reduced product of response rate and reduced episode duration. Similar to Goodwin & episode duration. Similar to Goodwin & Jamison (1990), a slightly higher weighted Jamison (1990), a slightly higher weighted response rate was found for patients in response rate was found for patients in manic episodes treated with valproic acid manic episodes treated with valproic acid than lithium (58.1 than lithium (58.1 v v. 55.0%) but a much . 55.0%) but a much lower response rate for patients in delower response rate for patients in depressed episodes (38.2 pressed episodes (38.2 v v. 66.7%) (23 source . 66.7%) (23 source references available from authors on rereferences available from authors on request). The average length of untreated epiquest). The average length of untreated episodes of mania and depression is estimated sodes of mania and depression is estimated to be 4 and 5 months, respectively (Angst to be 4 and 5 months, respectively (Angst & Sellaro, 2000) . Therefore an initial re-& Sellaro, 2000). Therefore an initial response (within 1 month) will reduce by sponse (within 1 month) will reduce by 75% the time spent in mania and by 80% 75% the time spent in mania and by 80% the time spent depressed. A prophylactic the time spent depressed. A prophylactic treatment effect was also ascribed: a longitreatment effect was also ascribed: a longitudinal study of 360 people with bipolar tudinal study of 360 people with bipolar disorder adherent to lithium treatment for disorder adherent to lithium treatment for at least 1 year observed a larger reduction at least 1 year observed a larger reduction of time spent in mania than depression of time spent in mania than depression ) found a trend favouring a longer time before relapse for valproic acid longer time before relapse for valproic acid (median (median¼275 days) compared with lithium 275 days) compared with lithium (median (median¼189 days). Given a ceiling effect 189 days). Given a ceiling effect of 1-year follow-up, small sample sizes of 1-year follow-up, small sample sizes and exclusion of severe cases, the implied and exclusion of severe cases, the implied 45% difference in time to relapse is poten-45% difference in time to relapse is potentially overstated, and accordingly a 10% tially overstated, and accordingly a 10% increased efficacy of valproic acid over increased efficacy of valproic acid over lithium in lengthening time to relapse was lithium in lengthening time to relapse was modelled (half and double this amount modelled (half and double this amount were assessed via sensitivity analysis).
were assessed via sensitivity analysis).
A secondary effect of treatment -re-A secondary effect of treatment -reduction duction of the case fatality rate -was also of the case fatality rate -was also ascribed to lithium (though not to other ascribed to lithium (though not to other treatments in the base-case analysis, owing treatments in the base-case analysis, owing to a current absence of evidence; Goodwin to a current absence of evidence; Goodwin et al et al, 2003 ). An optimistic estimate comes , 2003). An optimistic estimate comes from a multicentre study by Wolf from a multicentre study by Wolf et al et al (1996) , who derived a standardised mortal-(1996), who derived a standardised mortality ratio of 1.1 (natural and unnatural ity ratio of 1.1 (natural and unnatural causes of death) for 827 patients treated causes of death) for 827 patients treated in lithium clinics over an average period in lithium clinics over an average period of 7 years. A less optimistic estimateof 7 years. A less optimistic estimatebecause it includes studies from the prebecause it includes studies from the prelithium era -comes from the meta-analysis lithium era -comes from the meta-analysis by Harris & Barraclough (1998), who by Harris & Barraclough (1998), who found a standardised mortality ratio of found a standardised mortality ratio of 2.0 for both natural and unnatural causes 2.0 for both natural and unnatural causes (1.5 for natural causes only; 9.2 for un-(1.5 for natural causes only; 9.2 for unnatural causes only), which is consistent natural causes only), which is consistent with a review of 22 studies by Tondo with a review of 22 studies by Tondo et al et al (2001 (2001b b) . A standardised mortality ratio of ). A standardised mortality ratio of 1.5 was used in our base-case analysis for 1.5 was used in our base-case analysis for people with bipolar disorder treated with people with bipolar disorder treated with lithium, corresponding to a 65% reduction lithium, corresponding to a 65% reduction in the instantaneous rate of case fatality. in the instantaneous rate of case fatality. Variations from these estimates were Variations from these estimates were examined via sensitivity analysis. examined via sensitivity analysis.
Changes in disability and case fatality Changes in disability and case fatality require adjustment for intervention require adjustment for intervention 5 61 5 61 AUTHOR'S PROOF AUTHOR'S PROOF 6 (1 (17 7 B) B) 6 6 (1 (17 7C). C). 3. Rate shown is for developing sub-regions (10% higher rates were used for developed regions). 3. Rate shown is for developing sub-regions (10% higher rates were used for developed regions).
coverage, as well as rates of adherence to coverage, as well as rates of adherence to intervention. Based on the significant intervention. Based on the significant underrecognition and consequent treatment underrecognition and consequent treatment gap for bipolar disorder, a target coverage gap for bipolar disorder, a target coverage rate of 50% was set for all sub-regions rate of 50% was set for all sub-regions (Kohn (Kohn et al ) found adherence rates for lithium to fall found adherence rates for lithium to fall in the range 47-72%. We considered the in the range 47-72%. We considered the upper end of this range to reflect rates upper end of this range to reflect rates found in controlled trial settings and the found in controlled trial settings and the lower end to be a closer estimate of reallower end to be a closer estimate of realworld effectiveness. Since our estimates of world effectiveness. Since our estimates of efficacy efficacy already incorporate an element already incorporate an element of nonof non-adherence (about 30%, see above), adherence (about 30%, see above), we apply a 'real-world' adjustment factor we apply a 'real-world' adjustment factor (of two-thirds) to obtain a more representa-(of two-thirds) to obtain a more representative estimate of real-world adherence to tive estimate of real-world adherence to lithium (e.g. 70% lithium (e.g. 70%6 666% 66%¼47%). The lit-47% 
Estimation of intervention costs Estimation of intervention costs
Two service models were evaluated, a Two service models were evaluated, a hospital-based in-patient model and a hospital-based in-patient model and a community-based out-patient model. ). Annual expected resource requirements -which did not vary between requirements -which did not vary between regions because the same level of effective regions because the same level of effective coverage is being modelled -included daily coverage is being modelled -included daily drug supply (e.g. 1200 mg lithium carbodrug supply (e.g. 1200 mg lithium carbonate), blood monitoring and other tests nate), blood monitoring and other tests (monthly for lithium treatment, every 2 (monthly for lithium treatment, every 2 months for valproic acid), psychosocial months for valproic acid), psychosocial support (eight sessions per year, where apsupport (eight sessions per year, where applicable), monthly out-patient attendances plicable), monthly out-patient attendances and primary care attendances (20-30% of and primary care attendances (20-30% of cases, with an average of six to eight visits). cases, with an average of six to eight visits). In-patient hospital and residential care In-patient hospital and residential care differed according to the service model: differed according to the service model: for the hospital-based service model, 40% for the hospital-based service model, 40% of depressive episodes and 45-50% of of depressive episodes and 45-50% of manic episodes were estimated to lead to manic episodes were estimated to lead to an acute psychiatric admission, average an acute psychiatric admission, average length of stay 21-28 days (10-20% of length of stay 21-28 days (10-20% of patients were estimated to reside in patients were estimated to reside in longer-term psychiatric facilities); for the longer-term psychiatric facilities); for the community-based model, admission rates community-based model, admission rates to acute psychiatric wards for depression to acute psychiatric wards for depression (15%) and mania (25%) were estimated (15%) and mania (25%) were estimated to be lower, as were the numbers of to be lower, as were the numbers of patients expected to require residential care patients expected to require residential care support in community-based housing (5-support in community-based housing (5-
; see WHO-CHOICE website at http://www.who.int/evidence/cea) to give http://www.who.int/evidence/cea) to give an annual cost per treated case, which an annual cost per treated case, which was then applied to the 50% of cases in was then applied to the 50% of cases in the population that are modelled to be the population that are modelled to be exposed to the intervention strategies. exposed to the intervention strategies. Programme-level costs of central adminisProgramme-level costs of central administration (planning, implementation, monitration (planning, implementation, monitoring) and training (adaptation of toring) and training (adaptation of guidelines, printing of materials) were also guidelines, printing of materials) were also derived for each sub-region. All baseline derived for each sub-region. All baseline analysis costs for the 10-year implementaanalysis costs for the 10-year implementation period were discounted at 3% and extion period were discounted at 3% and expressed in international dollars (I$), which pressed in international dollars (I$), which adjusts for differences in the purchasing adjusts for differences in the purchasing power of countries and thereby facilitates power of countries and thereby facilitates comparison within and across sub-regions comparison within and across sub-regions (i.e. I$1.00 buys the same quantity of (i.e. I$1.00 buys the same quantity of healthcare resources in China or India as healthcare resources in China or India as it does in the USA). it does in the USA).
Uncertainty analysis Uncertainty analysis
One-way sensitivity analyses were perOne-way sensitivity analyses were performed, first on the impact on final costformed, first on the impact on final costeffectiveness analysis of analytical social effectiveness analysis of analytical social preferences such as discounting and agepreferences such as discounting and ageweighting, and second on key drivers of weighting, and second on key drivers of cost (unit price of healthcare services, procost (unit price of healthcare services, proportion of patients using secondary serportion of patients using secondary services) and treatment effectiveness (changes vices) and treatment effectiveness (changes in mortality, disability and adherence). in mortality, disability and adherence). Best-and worst-case scenarios were also Best-and worst-case scenarios were also generated; these incorporated the combined generated; these incorporated the combined impact of upper and lower values. impact of upper and lower values.
RESULTS RESULTS
Intervention effects Intervention effects
Total DALYs averted annually by first-line Total DALYs averted annually by first-line treatment of bipolar disorder with lithium treatment of bipolar disorder with lithium or valproic acid (with and without or valproic acid (with and without psychosocial care) are reported for each psychosocial care) are reported for each sub-region in Table 3 . Interventions are sub-region in Table 3 . Interventions are estimated to avert between 276 and 443 estimated to avert between 276 and 443 DALYs per million total population in DALYs per million total population in high-mortality, developing sub-regions high-mortality, developing sub-regions (AfrD, AfrE, AmrD, EmrD and SearD; (AfrD, AfrE, AmrD, EmrD and SearD; see Table 1 for illustrative countries in these see Table 1 for illustrative countries in these sub-regions) and 375-517 DALYs in the resub-regions) and 375-517 DALYs in the remaining sub-regions (lower health gains in maining sub-regions (lower health gains in high-mortality, developing sub-regions are high-mortality, developing sub-regions are due to a higher risk of disablement or predue to a higher risk of disablement or premature death from other causes). Corremature death from other causes). Corresponding results for 'disability-free days' sponding results for 'disability-free days' gained per treated case range from 53 to gained per treated case range from 53 to 67 days per year. Implemented at a 50% 67 days per year. Implemented at a 50% coverage level, and expressed as a procoverage level, and expressed as a proportion of the current reported burden of portion of the current reported burden of bipolar disorder (World bipolar disorder (World Health OrganizaHealth Organization, 2001), populationtion, 2001), population-level health gain level health gain associated with these inter associated with these interventions ventions amounts to 11-19% in highamounts to 11-19% in high-mortality, mortality, developing sub-regions, 15-25% in lowdeveloping sub-regions, 15-25% in lowmortality, developing sub-regions (AmrB, mortality, developing sub-regions (AmrB, EmrB, SearB and WprB) and 26-33% in EmrB, SearB and WprB) and 26-33% in developed sub-regions (AmrA, EurA, EurB, developed sub-regions (AmrA, EurA, EurB, EurC and WprA). Greater averted burden EurC and WprA). Greater averted burden in developed regions results from higher rates in developed regions results from higher rates of current effective treatment coverage. of current effective treatment coverage.
Differences in the effectiveness of the Differences in the effectiveness of the four interventions in the base-case analysis four interventions in the base-case analysis are modest, but strategies using lithium are modest, but strategies using lithium generate marginally greater populationgenerate marginally greater populationlevel health gain than those with valproic level health gain than those with valproic acid, on account of the additional impact acid, on account of the additional impact of lithium on case fatality rates. Adjuvant of lithium on case fatality rates. Adjuvant psychosocial treatment provided in psychosocial treatment provided in tandem with mood stabiliser drugs also tandem with mood stabiliser drugs also improves out improves outcomes by approximately 10%, comes by approximately 10%, reflecting the improved adherence modelled. reflecting the improved adherence modelled.
Intervention costs Intervention costs
Intervention costs, both per million total Intervention costs, both per million total population and per treated case, are prepopulation and per treated case, are presented in Table 4 . Hospital-based service sented in Table 4 . Hospital-based service models incur notably higher costs than models incur notably higher costs than community-based service models (35-50% community-based service models (35-50% in very low-income regions to as much as in very low-income regions to as much as 70% in high-income regions) as a result 70% in high-income regions) as a result of differences in the expected use of acute of differences in the expected use of acute in-patient and longer-term residential faciin-patient and longer-term residential facilities. The total programme-and patientlities. The total programme-and patientlevel cost for interventions implemented level cost for interventions implemented via a community-based out-patient model, via a community-based out-patient model, in millions of international dollars per in millions of international dollars per million population (therefore equivalent million population (therefore equivalent to cost per capita), ranged from 0.85 to to cost per capita), ranged from 0.85 to 1.78 in high-mortality, developing sub-1.78 in high-mortality, developing subregions, 1.77-3.23 in low-mortality, regions, 1.77-3.23 in low-mortality, Within sub-regions and service models, Within sub-regions and service models, variations in intervention costs were very variations in intervention costs were very modest, which is attributable to the fact modest, which is attributable to the fact that additional costs of valproic acid over that additional costs of valproic acid over lithium (I$168 per year) and adjuvant lithium (I$168 per year) and adjuvant psychosocial treatment were expected to psychosocial treatment were expected to slightly reduce the need for in-patient care. slightly reduce the need for in-patient care. This modelled cost-offset effect is more This modelled cost-offset effect is more pronounced in high-income sub-regions pronounced in high-income sub-regions where the unit cost of an in-patient day is where the unit cost of an in-patient day is high, resulting in valproic acid becoming high, resulting in valproic acid becoming a marginally less expensive intervention a marginally less expensive intervention strategy than lithium. In low-income substrategy than lithium. In low-income subregions, lithium is estimated to be the regions, lithium is estimated to be the cheaper option. cheaper option.
Intervention cost-effectiveness Intervention cost-effectiveness
When total population-level costs and When total population-level costs and effects are merged to produce average effects are merged to produce average cost-effectiveness ratios (Table 5) , it cost-effectiveness ratios (Table 5) , it becomes apparent that a community-based becomes apparent that a community-based approach represents a more efficient approach represents a more efficient strategy than a hospital-based approach strategy than a hospital-based approach for addressing the current burden of bipolar for addressing the current burden of bipolar disorder (cost-effectiveness ratios are estidisorder (cost-effectiveness ratios are estimated to mated to be 25-40% lower). Differences be 25-40% lower). Differences in costin cost-effectiveness ratio between intereffectiveness ratio between interventions are modest, but in all sub-regions ventions are modest, but in all sub-regions the single most cost-effective strategy the single most cost-effective strategy for the base-case analysis is lithium with for the base-case analysis is lithium with psychosocial care, delivered within a psychosocial care, delivered within a community-based service framework, community-based service framework, each averted DALY costing I$2165-3830 each averted DALY costing I$2165-3830 in high-mortality, developing sub-regions, in high-mortality, developing sub-regions, I$3953-6475 in low-mortality, developing I$3953-6475 in low-mortality, developing 
Uncertainty analysis Uncertainty analysis
Substitution of the baseline discount rate of Substitution of the baseline discount rate of 3% with values of 0% and 6% altered total 3% with values of 0% and 6% altered total costs and average cost-effectiveness ratios costs and average cost-effectiveness ratios for all interventions by +14% and for all interventions by +14% and 7 711%, 11%, respectively. The removal of age-weighting respectively. The removal of age-weighting had a larger impact on results, reducing had a larger impact on results, reducing health health gain estimates by 11-23% across gain estimates by 11-23% across sub-regions (resulting in an increase of sub-regions (resulting in an increase of 13-30% in average cost-effectiveness 13-30% in average cost-effectiveness ratios). ratios).
One-way sensitivity analysis showed One-way sensitivity analysis showed that cutting the impact of lithium on case that cutting the impact of lithium on case fatality rates by half (from 65% to fatality rates by half (from 65% to 32.5%, equivalent to a revised standardised 32.5%, equivalent to a revised standardised mortality ratio of 2.0 compared with 1.5 mortality ratio of 2.0 compared with 1.5 for the base case) reduced DALYs averted for the base case) reduced DALYs averted by approximately 8%; attribution of a by approximately 8%; attribution of a small anti-suicide effect for valproic acid small anti-suicide effect for valproic acid (a reduction of 16%, standardised mortal-(a reduction of 16%, standardised mortality ratio 2.25) increased total health gain ity ratio 2.25) increased total health gain by 4%. Either change is enough to remove by 4%. Either change is enough to remove 5 6 3 5 6 3 AUTHOR'S PROOF AUTHOR'S PROOF v. combination treatments (a combination treatments (a lower value of 5% and an upper value of lower value of 5% and an upper value of 15%, compared with a baseline difference 15%, compared with a baseline difference of 10%) changed baseline effectiveness of 10%) changed baseline effectiveness results by 10-20%. results by 10-20%.
Best-and worst-case scenarios were Best-and worst-case scenarios were derived for cost-effectiveness by according derived for cost-effectiveness by according lower and upper 95% CIs to the unit costs lower and upper 95% CIs to the unit costs of health services, the proportion of cases of health services, the proportion of cases using secondary care hospital services using secondary care hospital services (relative changes of 20-50%, for example (relative changes of 20-50%, for example an admission rate of 30% rather than an admission rate of 30% rather than 20%) and number of psychosocial treat-20%) and number of psychosocial treatment sessions, in addition to the upper ment sessions, in addition to the upper and lower values reported above for treatand lower values reported above for treatment response and adherence. Under the ment response and adherence. Under the best-case scenario, total costs were 31-best-case scenario, total costs were 31-47% lower for the hospital service model 47% lower for the hospital service model and 20-37% lower for the community serand 20-37% lower for the community service model, total effects were 18-39% vice model, total effects were 18-39% higher (including a potential impact of higher (including a potential impact of valproic acid on suicide rates), thereby valproic acid on suicide rates), thereby lowering the overall cost per DALY averted lowering the overall cost per DALY averted by approximately half. Results for the by approximately half. Results for the worst-case scenario were in the same range; worst-case scenario were in the same range; in this case increases of close to 45-75% in in this case increases of close to 45-75% in costs and 23-30% less health gain led to costs and 23-30% less health gain led to average cost-effectiveness ratios 120-average cost-effectiveness ratios 120-150% higher than their baseline values. 150% higher than their baseline values. To illustrate, the expected cost per DALY To illustrate, the expected cost per DALY for community-based lithium treatment in for community-based lithium treatment in the Western Pacific sub-region WprB the Western Pacific sub-region WprB (baseline value I$4989) ranged from (baseline value I$4989) ranged from I$2771 to I$10 952. The principal finding I$2771 to I$10 952. The principal finding from these multiway sensitivity analyses from these multiway sensitivity analyses was that lithium-based treatments remain was that lithium-based treatments remain the cost-effective choice in high-mortality the cost-effective choice in high-mortality developing sub-regions, whereas in the developing sub-regions, whereas in the three high-income sub-regions of America, three high-income sub-regions of America, 5 6 4 5 6 4 AUTHOR'S PROOF AUTHOR'S PROOF Table 4  Table 4 Costs of bipolar disorder treatment (I$2000) at a coverage rate of 50%
Costs of bipolar disorder treatment (I$2000) at a coverage rate of 50% AUTHOR'S PROOF AUTHOR'S PROOF (2001) for an intervention to be considered cost-effective. 3. Total discounted population cost (I$) divided by total discounted and age-weighted population health gain (DALYs averted). 3. Total discounted population cost (I$) divided by total discounted and age-weighted population health gain (DALYs averted). 4. Total discounted and age-weighted population health gain (disability-adjusted life years (DALYs) averted) divided by discounted population cost (million international dollars, I$m). 4. Total discounted and age-weighted population health gain (disability-adjusted life years (DALYs) averted) divided by discounted population cost (million international dollars, I$m).
pharmaco pharmacotherapy alone; and hospital-based therapy alone; and hospital-based v. v. communitycommunity-based service models. Valbased service models. Valproic acid was modelled to have a marginproic acid was modelled to have a marginally greater prophylactic treatment effect ally greater prophylactic treatment effect and better adherence than lithium, but a and better adherence than lithium, but a lower acute treatment effect for depressive lower acute treatment effect for depressive episodes and no effect on case fatality. It episodes and no effect on case fatality. It is the expected health gain associated with is the expected health gain associated with a demonstrated impact on suicide rates a demonstrated impact on suicide rates (Tondo (Tondo et al Adjuvant psychosocial treatment alongside Adjuvant psychosocial treatment alongside use of mood-stabilising drugs is expected use of mood-stabilising drugs is expected to improve the cost-effectiveness of treatto improve the cost-effectiveness of treatment for bipolar disorder, as a result of ment for bipolar disorder, as a result of improved adherence (which in effect improved adherence (which in effect reduces the proportion of time spent in a reduces the proportion of time spent in a manic or depressed state), and because the manic or depressed state), and because the additional costs of psychosocial treatment additional costs of psychosocial treatment are largely offset by a reduced probability are largely offset by a reduced probability of admission to hospital. Finally, and again of admission to hospital. Finally, and again because of expected reductions in the use of because of expected reductions in the use of expensive hospital in-patient facilities, expensive hospital in-patient facilities, treatments provided within a communitytreatments provided within a communitybased service model offer a more efficient based service model offer a more efficient (and because of improved accessibility, (and because of improved accessibility, more equitable) use of resources than more equitable) use of resources than hospital-based services. hospital-based services. At a broader, sectoral level of compariAt a broader, sectoral level of comparison, interventions for bipolar disorder are son, interventions for bipolar disorder are not substantially different from each other. not substantially different from each other. Expressed in relation to gross national Expressed in relation to gross national income, the cost-effectiveness ratios income, the cost-effectiveness ratios for community-based interventions fall for community-based interventions fall between one and three times the gross between one and three times the gross national income per capita, a range connational income per capita, a range considered by the Commission on Macrosidered by the Commission on Macroeconomics and Health (2001; p. 103) to economics and Health (2001; p. 103) to be 'cost-effective' (as opposed to 'very costbe 'cost-effective' (as opposed to 'very costeffective', below average gross national effective', below average gross national income per capita; or 'not cost-effective', income per capita; or 'not cost-effective', more than three times gross national inmore than three times gross national income per capita). Comparisons with other come per capita). Comparisons with other studies are limited owing to the aggregate studies are limited owing to the aggregate level of analysis employed here; however, level of analysis employed here; however, our results for the Western Pacific subour results for the Western Pacific subregion WprA (which includes Australia) region WprA (which includes Australia) can be compared with the recent study by can be compared with the recent study by Sanderson Sanderson et al et al (2003) ; our estimated cost (2003); our estimated cost of I$20 000-22 000 for each DALY averted of I$20 000-22 000 for each DALY averted by community-based treatment is slightly by community-based treatment is slightly higher than their estimated cost for current higher than their estimated cost for current and optimal treatment (Aus$24 000, or and optimal treatment (Aus$24 000, or I$18 200), which can be attributed to I$18 200), which can be attributed to our inclusion of programme-level costs, a our inclusion of programme-level costs, a higher expected rate of in-patient admishigher expected rate of in-patient admission for mania and also greater downsion for mania and also greater downward adjustment of efficacy estimates for ward adjustment of efficacy estimates for 'real-world' effectiveness at the population 'real-world' effectiveness at the population level. level.
Compared with many other strategies Compared with many other strategies analysed to date under the WHO-CHOICE analysed to date under the WHO-CHOICE project -including population-based interproject -including population-based interventions to reduce heavy alcohol use, ventions to reduce heavy alcohol use, smoking and cardiovascular diseasesmoking and cardiovascular diseasebipolar disorder interventions have a bipolar disorder interventions have a relatively high ratio of cost to health outrelatively high ratio of cost to health outcome, and exceed the average cost per come, and exceed the average cost per averted DALY for efficient primary-careaverted DALY for efficient primary-carebased depression interventions by a factor based depression interventions by a factor of 4-6 (Chisholm of 4-6 (Chisholm et al et al, 2004) . Such a find-, 2004). Such a finding is hardly surprising in terms of costs, ing is hardly surprising in terms of costs, given the multiple health service needs of given the multiple health service needs of persons with a diagnosis of bipolar dispersons with a diagnosis of bipolar disorder, but does serve to highlight the rather order, but does serve to highlight the rather modest impact of these interventions on the modest impact of these interventions on the natural course of this disorder. Indeed, even natural course of this disorder. Indeed, even at a population treatment coverage rate of at a population treatment coverage rate of 50%, modelled interventions are only able 50%, modelled interventions are only able to avert between 10 and 33% of the burto avert between 10 and 33% of the burden, which points to a clear need to further den, which points to a clear need to further develop culturally appropriate psychosocial develop culturally appropriate psychosocial approaches capable of delivering improved approaches capable of delivering improved long-term functioning over and above long-term functioning over and above shorter-term considerations such as medishorter-term considerations such as medication adherence (e.g. 
Limits and limitations Limits and limitations of economic modelling of economic modelling
In common with other modelling studies, In common with other modelling studies, this analysis is a highly restricted representhis analysis is a highly restricted representation of reality. Bipolar disorder has a tation of reality. Bipolar disorder has a heterogeneous course, with patients experiheterogeneous course, with patients experiencing marked differences in rates of encing marked differences in rates of cycling between different mood states, cycling between different mood states, which is not well captured here. Separate which is not well captured here. Separate sub-analyses for 'rapid cyclers' would be sub-analyses for 'rapid cyclers' would be expected to reveal higher costs and worse expected to reveal higher costs and worse outcomes, for example, as might an analyoutcomes, for example, as might an analysis that would take into account the sis that would take into account the full range of possible comorbidities. In full range of possible comorbidities. In modelling the 'average' patient with bipolar modelling the 'average' patient with bipolar I disorder, we also make use of best avail-I disorder, we also make use of best available evidence on sub-regional epidemiology able evidence on sub-regional epidemiology and the expected impact of interventions, and the expected impact of interventions, which for many developing regions has which for many developing regions has necessitated extrapolation from neighbournecessitated extrapolation from neighbouring regions or from the international literaing regions or from the international literature. Use of a population-level measure of Use of a population-level measure of health gain such as the DALY has health gain such as the DALY has advantages -in terms of comparability advantages -in terms of comparability with other diseases, for instance -but does with other diseases, for instance -but does not encompass the full range of consenot encompass the full range of consequences that may follow from intervention. quences that may follow from intervention. For bipolar disorder, important additional For bipolar disorder, important additional benefits of treatment include reduction of benefits of treatment include reduction of family burden (including informal carefamily burden (including informal caregiving time) and reduced absenteeism and giving time) and reduced absenteeism and unemployment (productivity). A recent unemployment (productivity). A recent cost-of-illness study of bipolar disorder in cost-of-illness study of bipolar disorder in the UK estimated that no less than 86% the UK estimated that no less than 86% of total societal costs were attributable to of total societal costs were attributable to these indirect costs, mainly due to excess these indirect costs, mainly due to excess unemployment Baseline results showed lithium to be no more costly yet more effective than valproic acid, assuming an anti-suicidal effect for lithium but not for valproic acid. valproic acid, assuming an anti-suicidal effect for lithium but not for valproic acid. The most cost-effective interventions under best-, worst-and base-case scenarios were combination strategies of a mood stabiliser plus psychosocial treatment were combination strategies of a mood stabiliser plus psychosocial treatment delivered within a community-based service framework. delivered within a community-based service framework. The analysis restricted itself to the health system; wider economic consequences of bipolar disorder and its treatment, including lost/restored work opportunities, were bipolar disorder and its treatment, including lost/restored work opportunities, were not measured. not measured.
LIMITATIONS LIMITATIONS
